Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4050 in newly diagnosed locoregionally advanced head and neck squamous cell carcinoma
NCT04183166Phase 2Active, not recruiting
- Sponsor
- Transgene SA
- Start
- Dec 2019
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of TG4050 in head and neck squamous cell carcinoma (HNSCC), sponsored by Transgene SA. Started Dec 2019; status: active, not recruiting.
02
Drugs
TG4050
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04183166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183166.